Avandia Diabetes Drug
Avandia (generic: rosiglitazone) is a diabetes drug manufactured by GlaxoSmithKline. Research has shown that Avandia users face increased risks such as heart attack, dangerously low blood sugar levels, liver toxicity and low blood pressure. The Food and Drug Administration (FDA) has linked Avandia to 83,000 heart attacks between 1999 and 2007, some of which resulted in death. Avandia was required to carry a black box warning (the severest warning the FDA can attach) indicating the high risk of heart problems for users. Research dating back to 2007 indicated the elevated risk of heart attack from Avandia, but GlaxoSmithKline did nothing to notify consumers or remove the dangerous drug from the market. Finally, in September 2010, drug regulators in the US and Europe made a rare, coordinated decision to suspend sales of Avandia entirely in Europe and only allow sales in the US to patients who were first made aware of the grave risks.